Background. Patients repeatedly presenting with medically unexplained symptoms (MUS) to their GPs, suffer from their symptoms. Experts in the field suggest a multicomponent approach for these patients. Brief multimodal psychosomatic therapy (BMPT) is such an intervention. Objectives. To test the systematic identification of eligible patients, acceptability of BMPT and potential treatment effects of BMPT. Methods. The participants in this randomized pilot trial, patients consulting their GPs more than once with MUS, were randomized to intervention [usual care (UC) and additional BMPT] or control condition (UC alone). We monitored the number of patients identified and recruited, trial recruitment and retention. Potential treatment effects were measured with perceived symptom severity [Visual Analogue Scale (VAS)]; patients' self-rated symptoms of distress, depression, anxiety and somatization [Four-Dimensional Symptom Questionnaire (4DSQ)]; symptoms of hyperventilation [Nijmegen Hyperventilation List (NHL)]; physical and mental health status and quality of life [Short-Form Health Survey-36 items (SF-36)]; and level of functioning (measure of general functioning). Followup was 1 year. Results. A total of 42 patients could be included in the trial. Four patients withdrew after randomization and two patients were lost to follow-up, resulting in 36 patients (86%). During the 12-month follow-up after BMPT, there was an improvement in perceived symptom severity [adjusted mean difference −2.0, 95% confidence interval (CI) −3.6 to −0.3], in somatization (adjusted mean difference −4.4, 95% CI −7.5 to −1.4) and in symptoms of hyperventilation (adjusted mean difference −5.7, 95% CI −10.5 to −0.8).
Introduction
Physical symptoms, such as headache, back pain, dizziness and fatigue, are common reasons for visiting a primary health care. In 25-50% of all symptoms seen in primary care, no underlying physical disease can be identified (1, 2) . Although only a minority (2.5%) of patients keep presenting with medically unexplained symptoms (MUS) to their GP, these chronic patients represent a major problem in health care (3, 4) . Patients frequently presenting MUS to their GPs, suffer from their symptoms, are functionally impaired, and are at risk of unnecessary and possibly harmful tests, referrals, treatment and high health care costs (5, 6) . Several treatments for patients with MUS have been described. However, a recent Cochrane review studying non-pharmacological interventions for MUS in primary care concluded that further research is needed to study various treatment modalities (other than cognitive behavioural therapy) in general and physical therapy in particular (7) . Experts in the field of MUS indicate that a multicomponent approach, in which creating a safe therapeutic environment, generic interventions (such as motivational interviewing, explaining and educating and regularly scheduled appointments) and specific interventions (such as cognitive approaches and activating therapy) is combined, is most helpful for patients with MUS (8) . Brief multimodal psychosomatic therapy (BMPT) is such a multicomponent approach. BMPT is delivered by physiotherapists or exercise therapists with a special interest in MUS. BMPT is a stepped-care and tailor-made approach, which focuses on the combination of physical, psychological and behavioural symptoms of stress in order to reduce bodily symptoms and to empower patients to assert control over factors that affect their health (9) . BMPT is regarded as an important treatment option for patients with MUS according to the GP guideline for MUS of the Dutch College of GPs (10) .
Although BMPT seems to be acceptable for patients with MUS in daily primary care, the effectiveness has not yet been proven by scientific research. To determine the feasibility of conducting a larger randomized clinical trial (RCT) on the (cost-)effectiveness of this multicomponent approach in patients with MUS in primary care, we designed a pilot RCT in which we examined the following components of feasibility: method of systematic identification of patients, trial recruitment and retention, acceptability of the BMPT and potential treatment effects.
Methods

Trial design
We designed a randomized controlled pilot trial with patients suffering from MUS in primary care. Patients were randomized to intervention [usual care (UC) and additional BMPT delivered by physiotherapists or exercise therapists with a special interest in MUS] or control condition (UC alone). All patients were followed up for 1 year. After randomization, all patients received the first questionnaires to assess baseline characteristics. Patients in the intervention group were asked to complete the questionnaires at baseline, at the end of the intervention (at ~3 months) and at 6 and 12 months. Patients in the control group completed the questionnaires at baseline and at 3, 6 and 12 months. In case of no response, we sent reminders to patients twice.
Setting and participants
Patients with MUS were recruited in six general practices during the consultations. As a requirement for participation, GPs needed to have the possibility to refer to a physiotherapist or exercise therapist with a special interest in MUS. GPs included patients who consulted their practice more than once for 1 or more of the 12 symptoms (stomach/ abdominal pain, back/neck/shoulder pain, pain in arms/legs/joints, headache, chest pain, dizziness, fainting spells, palpitations of the heart, shortness of breath, nausea/indigestion, feeling tired and sleeping disorders) for which no organic pathology could be found. These 12 symptoms are regarded as the most commonly presented MUS in primary care and are derived from the PHQ-15, a validated questionnaire for screening of somatoform disorders in primary care (11) .
Exclusion criteria were medically 'explained' symptoms, age <18 or >80 years, severe chronic diseases (e.g. Parkinsonism, heart failure, stroke), long-lasting injury treatment, palliative care, severe psychiatric disorders (e.g. severe depression, psychosis) and not being able to speak, read and write in Dutch.
Intervention
BMPT was developed from the broad concept of the biopsychosocial model in which illness is viewed as a result of interacting mechanisms at the biomedical, interpersonal and environmental levels. BMPT implies that patients' symptoms, illness beliefs, anxiety, concerns, illness behaviour and social environment are addressed. It is a tailor-made treatment that is based on the patients' reason to seek help for the symptoms and includes the following modules: (i) psychoeducation, (ii) relaxation therapy and mindfulness, (iii) cognitive behavioural approaches and (iv) activating therapy. BMPT is captured in a treatment protocol in which the therapists are able to change the intensity, frequency and order of the four modules in order to deliver a tailor-made approach and fits within the recommendations of the recent Cochrane review on non-pharmacological interventions of somatoform disorders and MUS (7) .
Patients randomized to the intervention group were invited to attend at most nine sessions of BMPT. The number of sessions depended on the severity of symptoms and functional limitations. Each session lasted about 45 minutes. Furthermore, patients were asked to practice relaxation techniques, coping skills and the cognitive behavioural interventions in daily life. The UC consisted of the care provided by the GP and other health care professionals.
Recruitment and signed informed consent
Participating GPs were asked to enrol each consecutive eligible patient and include 10 patients each. The GPs presented written information and an informed consent form. GPs sent a reminder to non-responding patients after 2 weeks. Written informed consent was obtained from all participants.
A few activities were performed to enhance the inclusion of patients with MUS: (i) monthly newsletters in which participating GPs were informed about the progress of the study, (ii) 2-week appointments by phone to remind participating GPs about the study and (iii) 3-month visits of the practice site to answer questions and support GPs to identify eligible patients.
Randomization
The participants were randomized by the research assistant directly after receiving the written informed consent. The research assistant was unaware of the health status of the participant and used a computer-generated permuted block randomization table. Patients randomized to the UC group could receive BMPT after completion of the study. After randomization, the patient's identification number was matched with the corresponding name to inform the participant about the allocation. Their GPs were informed about the allocation through a letter.
Outcome measures
We aimed to systematically evaluate the number of patients identified and recruited in the pilot trial, the time needed to include eligible patients, the number of withdrawals in the intervention and control group, compliance in the therapy group and the number of patients who completed the questionnaires. Patients rated satisfaction with the received therapy in the intervention group on a five-point Likert scale (extremes labelled as very dissatisfied to very satisfied).
Potential treatment effects were measured for perceived symptom severity on a Visual Analogue Scale (VAS) (range 0-10; 10 represents most severe symptoms) and patients' self-rated symptoms of distress, depression, anxiety and somatization [Four-Dimensional Symptom Questionnaire (4DSQ)]. 4DSQ subscales distress and somatization scores range from 0 to 32 (low: 0-10; moderate: 11-20; high: 21-32), subscale anxiety scores range from 0 to 24 (low: 0-7; moderate: 8-12; high [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and subscale depression scores range from 0 to 12 (low: 0-2; moderate 3-5; high 6-12), so higher scores represent worse health (12) . Furthermore, symptoms of hyperventilation [Nijmegen Hyperventilation List (NHL)] were assessed. NHL scores range from 0 to 64, where higher scores represent worse health (13) . Physical and mental health status and quality of life were measured with the Short-Form Health Survey-36 items (SF-36). SF-36 scores range from 0 to 100, where higher scores correspond to better health (14) . The nine subscales were summarized into the two summary measures of the SF-36: the Physical Component Summary (PCS) and the Mental Component Summary (MCS) (15) and the subscale health change (16) . Level of functioning was measured with measure of general functioning (MAF). MAF scores range from 0 to 10, where higher scores represent better health.
Baseline characteristics are as follows: age, gender, marital status, social economic status (employment and level of education), source of income, working hours, intensity and duration of MUS. Expectations about the prognosis of the complaints, with range 0-10 (10 represents expected complete improvement), and expectations about the effect of the treatment, ranging from 0 to 10 (10 represents very good expectations), were included in the baseline questionnaire.
Statistical analysis
The number of patients identified and recruited by the GP as well as the number of eligible patients who declined to enter the trial was analysed using descriptive statistics. The potential treatment effects were estimated using analysis of covariance (ANCOVA) with baseline value as a covariate. Linear mixed modelling was used to estimate treatment effects in time (i.e. time trend). In addition, we used the paired samples T-tests to test within-group differences between baseline measurements and 3-and 12-month follow-up, as our outcome measures at baseline showed a normal distribution (data not shown). Effect sizes (ES) were calculated with the adjusted differences between the groups (17) . Data analysis was performed according to the intention-to-treat principle, i.e. special care was taken to gather follow-up data on all patients, regardless of whether they complied to the intervention they were randomized to or not (18) . Differences in baseline characteristics were analysed by the Student's T-test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables. P values of <0.05 were considered statistically significant. We considered a 30% improvement within and between conditions as a clinically relevant improvement for all outcome measures (19) . All statistical analyses were performed using IBM SPSS Statistics 21.
Results
Systematic identification of eligible patients and recruitment
In April 2013, we started with six GPs in six different practices, who agreed to take part in this study. After 3 months, a total of 13 eligible patients with MUS were recruited by 2 of the 6 GPs identified, whereas we expected 6 GPs to find 60 eligible patients. Therefore, we asked six other GPs to participate in the study. Additionally, during the following 6 months, these 12 GPs identified 69 eligible patients with MUS. A total of 42 patients agreed to participate. Three GPs only identified 1 eligible patient, whereas 4 GPs identified >10 eligible patients. Enrolment of participants in the study is summarized in Figure 1 .
Patients' characteristics
Patients' sociodemographic and baseline clinical characteristics are shown in Table 1 . The most frequent physical complaint was fatigue (n = 12; 32%). Twenty-seven patients (71%) had little to moderate impairment in daily functioning, and 10 patients (26%) had severe impairment. The mean health expectation in the BMPT group was 5.1 (SD 2.9) and 3.9 (SD 2.8) in the UC group. The mean (SD) expectation of the treatment effect in the therapy group was 6.0 (1.6).
There were no significant differences in baseline characteristics between patients in the BMPT condition and patients in the UC condition. Scores on the 4DSQ and the SF-36 showed that patients face moderate impairment due to the symptoms.
Trial retention and acceptability of BMPT
Sixteen patients in the intervention group and 20 patients in the UC group completed the questionnaires. The monthly cost diaries were completed by 16 (100%) patients in the BMPT group and 19 (95%) patients in the UC group.
Two patients in the UC group received BMPT during the follow-up period due to strong preferences. Patients in the intervention group received 6.4 BMPT sessions on average (range 1-9) in a 3-month period. Thirteen (81%) patients were (very) satisfied and reported that the BMPT helped them to deal with their problems more effectively. One patient held a neutral opinion, and two patients were dissatisfied and disappointed with the treatment and were still seeking an explanation for their symptoms.
Estimates of potential treatment effects
Outcome measures were obtained for 36 (86%) patients. Outcome measures at baseline, after the 3-month follow-up and at the 12-month follow-up, are summarized in Table 2 . Patients in the BMPT group did not significantly differ from patients in the UC group with regard to baseline values of the outcome measures.
At 12-month follow-up, participants in the BMPT group reported a significantly greater and clinically relevant improvement in perceived symptom severity [adjusted mean difference −2.0, 95% confidence interval (CI) −3.6 to −0.3, P = 0.022], in somatization (adjusted mean difference −4.4, 95% CI −7.5 to −1.4, P = 0.005) and in symptoms of hyperventilation (adjusted mean difference −5.7, 95% CI −10.5 to −0.8, P = 0.025). In the within-group analysis, the BMPT group had improved significantly at 12-month followup with regard to the perceived symptom severity, the patients' self-rated symptoms of somatization (4DSQ) and the symptoms of hyperventilation and health change. Almost all outcome measures showed greater improvement in the BMPT group than in the UC group and were considered clinically relevant (19) . These were all medium to large effects according to Cohen Results concerning the adjusted differences between the groups (ANCOVA, adjusted for baseline characteristics) and the differences within the groups (paired samples T-tests) are summarized in Table 3 .
Furthermore, for the primary outcome measures 'perceived symptom severity' and 'somatization', the effect of the BMPT compared to the UC group significantly increased during each time point (at 3-, 6-and 12-month follow-up) (respectively, P = 0.037 and P = 0.008). A similar significant trend was observed for the secondary outcome measure 'symptoms of hyperventilation' (P = 0.052).
Discussion
Summary of main findings
This study is the first randomized pilot trial in which BMPT in patients with MUS in primary care is studied. Our pilot study shows that identification and recruitment of eligible patients by GPs during the consultation hours are troublesome. GPs face evident difficulties in identifying eligible patients during the consultation hours. Trial retention and acceptability of BMPT appears to be good as only two patients (5%) dropped out or were lost to follow-up. Furthermore, 36 patients (86%) completed all four questionnaires. A majority of the patients (81%) were satisfied about the BMPT they received. They indicated that BMPT helped them to deal with their problems more effectively. Therefore, we conclude that a larger trial studying the effectiveness of BMPT in patients with MUS in primary care is feasible.
Although the trial was not powered to detect treatment effects, we found that BMPT has the potential to result in symptom improvement in patients with MUS. However, the effectiveness of BMPT has to be confirmed in a larger, well-powered trial with more participating GPs and therapists.
Strengths and limitations of this study
Most research on treatment effects has been performed in patients with severe conditions of MUS in specialty care. Our study performed in daily general practice includes patients with mild to moderate MUS, because this patient group is considerably larger and much more gain for patients and society can be expected. As this pilot RCT was designed to evaluate trial procedures and retention, the small sample size seemed to be sufficient.
The results of the clinical effects found in the BMPT group should be interpreted with caution. Due to the difficulties in identifying eligible patients in this study, given the high numbers of patients encountering GPs with MUS, selection bias might have been introduced in our pilot trial. This is in accordance with our findings that patients included in the pilot trial had less severe symptoms than expected beforehand. Furthermore, we found large differences in the number of patients recruited per GP.
What did we learn from this pilot trial?
GPs experienced difficulties with the recruitment of patients with MUS during their consultation hours. Therefore, the recruitment of patients in our study took much more time than we expected beforehand. Reasons for difficulties with this incident sampling procedure could be that (i) patients are directly sent to the therapist because of the number and severity of the symptoms and were therefore not asked to participate in the study, (ii) potentially eligible patients have limited symptoms, (iii) patients do not have time to participate and (iv) recruiting incident cases and informing them about the study during consultation hours take extra time and do not have first priority for GPs. The problems GPs reported with regard to including patients in our study have also been reported by Oude Rengerink et al. (20) . They mentioned clinicians' time constraints, worry about the impact on doctor-patient relationship, concern for patients and loss of professional autonomy as important barriers for including patients. Patients mentioned preference for one form of treatment, dislike of the randomization, general discomfort with the research process and the presence of a no-treatment group as important barriers for participation. In our study, patients seem to encounter the same barriers.
Some of the outcome measures, for example, symptom severity, show no significant effect at 3-month follow-up and some significant effects in the long term (i.e. at 12-month follow-up). This might be the result of the fact that patients treated with BMPT learned to actively manage their symptoms on a biomedical, interpersonal and environmental level and were able to come to terms with changes in their behaviour. However, this self-management and these behavioural changes take time to be effective.
In the UC group, we found small improvements of some of the outcome measures after the 3-and 12-month follow-up. This might be the result of the natural course, regardless of the UC. Furthermore, regression to the mean might explain these small improvements in the UC group. In addition, it is not unlikely that special attention by the therapist led to an additional improvement in the intervention group and that participation in the study itself led to an additional improvement in the control group.
Comparison with other recruitment and intervention strategies
Previous studies of primary care interventions for patients with MUS showed different methods of identifying eligible patients. An intervention study by Rosendal et al. (21) used questionnaire sampling in which the practice assistants enrolled patients consecutively using inclusion criteria and questionnaires. However, this study demonstrated large variations in GPs' diagnoses of MUS. In a recent study by van Ravesteijn et al., (22) researchers provided the GPs with a list of their 10% most frequently attending patients in the past year, which they retrieved from the computerized database of the GPs. GPs applied exclusion criteria to this list of frequently attending patients and selected eligible patients. These patients received an invitation letter, and those interested were invited to a research interview conducted under the supervision of an experienced psychiatrist (22) . This method of selection of patients with MUS appeared to be an effective one. However, some researchers showed that frequent attendance is steady (23) in a considerable amount of patients and frequent attendance over a period of 2 years is more stable (24) .
Implications for future research
Although it is well known that GPs face difficulties in the communication and relationship with patients with MUS, further research is needed in order to understand the problems GPs face with the recruitment of patients with MUS in intervention studies. Furthermore, in this pilot trial BMPT has been proven to be an acceptable therapy for patients with MUS in primary care. As acceptable treatments for MUS in primary care are scarce, BMPT is a promising way forward for these often functionally impaired patients. However, further research (i.e. a larger RCT) is needed to establish the (cost-)effectiveness of BMPT for patients with MUS in primary care. A larger RCT should take into account the placebo effect of the frequent consultations with a therapist. Adding another control group, besides treatment as usual, for example, talkative therapy or relaxation therapy (one of the elements of BMPT), should be considered. Furthermore, a future trial would benefit from a longitudinal qualitative in-depth interview study alongside the trial in order to establish which components of BMPT contribute the most to patients' clinical improvement.
Conclusions
BMPT and the trial procedures that we used seem to be feasible and acceptable for patients with MUS in primary care. Patients with MUS were able and willing to participate, completed the questionnaires and accepted BMPT for their symptoms. However, further research is needed to establish the effectiveness of BMPT in primary care. Such research would benefit from using a prevalent sampling technique to identify a sufficient sample of eligible patients for the detection of statistically significant and clinically relevant treatment effects of BMPT.
